Compare CR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CR | BIO |
|---|---|---|
| Founded | 1855 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.3B |
| IPO Year | 2022 | 1994 |
| Metric | CR | BIO |
|---|---|---|
| Price | $202.12 | $359.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 3 |
| Target Price | $241.40 | ★ $356.67 |
| AVG Volume (30 Days) | ★ 399.0K | 222.7K |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | 23.96 | ★ 142.61 |
| EPS | 4.43 | ★ 11.25 |
| Revenue | $2,305,000,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $26.35 | N/A |
| Revenue Next Year | $6.06 | $1.86 |
| P/E Ratio | $47.28 | ★ $32.66 |
| Revenue Growth | ★ 8.16 | 0.65 |
| 52 Week Low | $159.58 | $236.73 |
| 52 Week High | $230.50 | $396.23 |
| Indicator | CR | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 42.74 |
| Support Level | $196.65 | $350.89 |
| Resistance Level | $210.63 | $392.10 |
| Average True Range (ATR) | 7.24 | 12.70 |
| MACD | 0.10 | -1.98 |
| Stochastic Oscillator | 33.99 | 15.43 |
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.